Related articles

Garetosmab (Pasatru)

Monoclonal antibody marketed as Pasatru by Regeneron; reported to reduce new abnormal bone formation by 90 percent in F.O.P.

• New Treatments Offer Hope for Patients with Runaway Bone Disorder F.O.P.